MedTrace Logo

Variability of Definitions for Survival Endpoints and Surrogate Properties for OS in Sarcoma Trials: a Meta-analysis

NCT02873923 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2846

Last updated 2021-01-25

Study results available
· View outcomes & findings →

Summary

The DATECAN-2 project aims at assessing the surrogate properties for OS of several time-to-event endpoints through meta-analyses of completed and published randomized controlled trials. Two main cancer localization are concerned: breast cancer and soft-tissue sarcomas. The impact of survival endpoints' definitions on the trials' results and conclusions will also be evaluated.

Conditions

Interventions

DRUG

undefined

Chemotherapy drug (meta-analyses of randomized trials)

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • Ligue contre le cancer, France

    collaborator OTHER

  • Institut du Cancer de Montpellier - Val d'Aurelle

    collaborator OTHER

  • Centre Georges Francois Leclerc

    collaborator OTHER

  • Institut Bergonié

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2017-01-01
Completion
2017-01-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02873923 on ClinicalTrials.gov